LT5143B - Monoamino sunaudojimo slopintojas - Google Patents

Monoamino sunaudojimo slopintojas Download PDF

Info

Publication number
LT5143B
LT5143B LT2003075A LT2003075A LT5143B LT 5143 B LT5143 B LT 5143B LT 2003075 A LT2003075 A LT 2003075A LT 2003075 A LT2003075 A LT 2003075A LT 5143 B LT5143 B LT 5143B
Authority
LT
Lithuania
Prior art keywords
methyl
phenyl
oxy
aminopropane
compound
Prior art date
Application number
LT2003075A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2003075A (en
Inventor
Edward Luis Mattiuz
John-Michael Sauer
William Joe Wheeler
David Taiwai Wong
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT2003075A publication Critical patent/LT2003075A/xx
Publication of LT5143B publication Critical patent/LT5143B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LT2003075A 2001-03-06 2003-08-11 Monoamino sunaudojimo slopintojas LT5143B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06

Publications (2)

Publication Number Publication Date
LT2003075A LT2003075A (en) 2004-03-25
LT5143B true LT5143B (lt) 2004-06-25

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003075A LT5143B (lt) 2001-03-06 2003-08-11 Monoamino sunaudojimo slopintojas

Country Status (35)

Country Link
US (2) US20040082666A1 (de)
EP (1) EP1379492B1 (de)
JP (1) JP2004525912A (de)
KR (1) KR20030092012A (de)
CN (1) CN1229331C (de)
AP (1) AP2003002855A0 (de)
AT (2) ATE396170T1 (de)
AU (1) AU2002245385B2 (de)
BR (1) BR0207716A (de)
CA (1) CA2440161A1 (de)
CH (1) CH695982A5 (de)
CZ (1) CZ20032380A3 (de)
DE (1) DE60226715D1 (de)
DK (1) DK200301267A (de)
EA (1) EA005768B1 (de)
EC (1) ECSP034760A (de)
EE (1) EE200300419A (de)
ES (2) ES2305221T3 (de)
FI (1) FI20031191L (de)
GB (1) GB2389851B (de)
HR (1) HRP20030710A2 (de)
HU (1) HUP0303341A3 (de)
IL (1) IL157779A0 (de)
LT (1) LT5143B (de)
LU (1) LU91038B1 (de)
LV (1) LV13119B (de)
NO (1) NO20033921L (de)
NZ (1) NZ527431A (de)
OA (1) OA12494A (de)
PL (1) PL363840A1 (de)
SE (1) SE526598C2 (de)
SK (1) SK10632003A3 (de)
TR (1) TR200705146T1 (de)
WO (1) WO2002070457A1 (de)
ZA (1) ZA200306882B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60226715D1 (de) * 2001-03-06 2008-07-03 Lilly Co Eli Monoamin-aufnahme-inhibitor
US20060241188A1 (en) * 2003-08-27 2006-10-26 Elililly And Company Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
EP0909754A1 (de) 1997-10-14 1999-04-21 Eli Lilly And Company Verfahren zur Herstellung chiraler Verbindungen
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
WO2000061540A1 (en) 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
EP1395253A2 (de) * 2000-11-15 2004-03-10 Eli Lilly And Company Behandlung von angstzuständen
DE60226715D1 (de) * 2001-03-06 2008-07-03 Lilly Co Eli Monoamin-aufnahme-inhibitor

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5023269A (en) 1986-12-22 1991-06-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
EP0909754A1 (de) 1997-10-14 1999-04-21 Eli Lilly And Company Verfahren zur Herstellung chiraler Verbindungen
WO1999018947A1 (en) 1997-10-14 1999-04-22 Eli Lilly And Company Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
WO2000061540A1 (en) 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E.J COREY, GREGORY A REICHARD: "Enantioselective and practical syntheses of R- and S-fluoxetines", TETRAHEDRON LETTERS, 1989, pages 5207, XP002112223, DOI: doi:10.1016/S0040-4039(01)93743-8
GREEN, WUTZ: "Protecting Groups in Chemical Synthesis (3nd ed.)"
THOMAS M. KOENIG, DAVID MITCHELL: "A convenient method for preparing enantiomerically pure norfluoxetine, fluoxetine and tomoxetine", TETRAHEDRON LETTERS, 1994, pages 1339, XP002121949, DOI: doi:10.1016/S0040-4039(00)76212-5
Y. GAO, K. B. SHARPLESS: "Asymmetric synthesis of both enantiomers of tomoxetine and fluoxetine. Selective reduction of 2,3-epoxycinnamyl alcohol with Red-Al", J. ORG. CHEM., 1988, pages 4084

Also Published As

Publication number Publication date
CN1229331C (zh) 2005-11-30
SE526598C2 (sv) 2005-10-18
CH695982A5 (de) 2006-11-15
SE0302361D0 (sv) 2003-09-03
FI20031191A7 (fi) 2003-08-25
EE200300419A (et) 2004-02-16
CA2440161A1 (en) 2002-09-12
FI20031191L (fi) 2003-08-25
HUP0303341A3 (en) 2007-03-28
HUP0303341A2 (hu) 2004-01-28
IL157779A0 (en) 2004-03-28
WO2002070457A1 (en) 2002-09-12
LU91038B1 (fr) 2003-09-11
GB2389851A (en) 2003-12-24
TR200705146T1 (tr) 2008-02-21
AT414238B (de) 2006-10-15
EA200300978A1 (ru) 2004-02-26
GB0323169D0 (en) 2003-11-05
KR20030092012A (ko) 2003-12-03
LT2003075A (en) 2004-03-25
WO2002070457A8 (en) 2004-06-03
PL363840A1 (pl) 2004-11-29
BR0207716A (pt) 2004-03-23
NO20033921L (no) 2003-11-05
GB2389851B (en) 2005-05-25
OA12494A (en) 2006-05-24
ES2305221T3 (es) 2008-11-01
ES2201942B2 (es) 2004-12-16
AP2003002855A0 (en) 2003-08-20
HRP20030710A2 (en) 2004-08-31
ZA200306882B (en) 2004-12-03
EP1379492B1 (de) 2008-05-21
SE0302361L (sv) 2003-09-03
EP1379492A1 (de) 2004-01-14
EA005768B1 (ru) 2005-06-30
DK200301267A (da) 2003-11-06
NO20033921D0 (no) 2003-09-04
ATE396170T1 (de) 2008-06-15
US20050209341A1 (en) 2005-09-22
JP2004525912A (ja) 2004-08-26
ECSP034760A (es) 2003-10-28
LV13119B (en) 2004-06-20
DE60226715D1 (de) 2008-07-03
ES2201942A1 (es) 2004-03-16
CZ20032380A3 (en) 2004-03-17
ATA90422002A (de) 2006-01-15
NZ527431A (en) 2005-05-27
US20040082666A1 (en) 2004-04-29
AU2002245385B2 (en) 2007-01-18
US7384983B2 (en) 2008-06-10
CN1494526A (zh) 2004-05-05
SK10632003A3 (sk) 2004-06-08

Similar Documents

Publication Publication Date Title
JP4833884B2 (ja) ３，３−ジフェニルプロピルアミンの新規な誘導体
TWI436762B (zh) 二環性γ－胺基酸衍生物
US11905276B2 (en) Bicyclic compound that acts as CRBN protein regulator
KR100192622B1 (ko) 페네타놀아민 화합물
EP1379492B1 (de) Monoamin-aufnahme-inhibitor
AU2002245385A1 (en) Inhibitor of monoamine uptake
US20130303786A1 (en) Benzylpiperizine compound
US20240122876A1 (en) Compositions and methods for the treatment of ocular disorders
US8536342B2 (en) Process for producing thiabenzoazulene-propionic acid derivative
AU2007201684A1 (en) Inhibitor of monoamine uptake
PT97858A (pt) Metodo para a preparacao de um composto dicloroanilina tendo um substituinte contendo um grupo piridinilo
JP2022515156A (ja) ボリナンセリンの重水素化形態および誘導体
JP2772650B2 (ja) 新規化合物およびその医薬的用途
US20110118358A1 (en) Deuterium-enriched salmeterol